Chemistry: molecular biology and microbiology – Maintaining blood or sperm in a physiologically active state...
Reexamination Certificate
2005-11-29
2009-06-30
Weber, Jon P (Department: 1657)
Chemistry: molecular biology and microbiology
Maintaining blood or sperm in a physiologically active state...
C435S068100, C424S529000, C514S006900, C530S354000, C530S363000, C530S380000, C530S385000, C530S812000
Reexamination Certificate
active
07553613
ABSTRACT:
Red blood cells are purified by defibrinating whole blood and then filtering the defibrinated whole blood, whereby at least a portion of a plasma component is separated from the red blood cells to form a suspension of red blood cells, thereby purifying the red blood cells. Whole blood is defibrinated by, for example, using a chemical coagulating agent or mechanical agitation. Separation of the plasma component from red blood cells can be completed by, for example, diafiltration. The suspension of red blood cells can then be employed to produce a hemoglobin-based oxygen carrier.
REFERENCES:
patent: 3864478 (1975-02-01), Bonhard
patent: 3973001 (1976-08-01), Jaeger et al.
patent: 3991181 (1976-11-01), Doczi
patent: 4001200 (1977-01-01), Bonsen et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4053590 (1977-10-01), Bonsen et al.
patent: 4061736 (1977-12-01), Morris et al.
patent: 4401652 (1983-08-01), Simmonds et al.
patent: 4439357 (1984-03-01), Bonhard et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4826811 (1989-05-01), Sehgal et al.
patent: 4857636 (1989-08-01), Hsia
patent: 4861867 (1989-08-01), Estep
patent: 5045529 (1991-09-01), Chiang
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5189146 (1993-02-01), Hsia
patent: 5194590 (1993-03-01), Sehgal et al.
patent: 5264555 (1993-11-01), Shorr et al.
patent: 5296465 (1994-03-01), Rausch et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5545328 (1996-08-01), Pliura et al.
patent: 5547873 (1996-08-01), Magneson et al.
patent: 5691452 (1997-11-01), Gawryl et al.
patent: 5691453 (1997-11-01), Wertz et al.
patent: 5753616 (1998-05-01), Rausch et al.
patent: 5808011 (1998-09-01), Gawryl et al.
patent: 5840852 (1998-11-01), Rausch et al.
patent: 5854209 (1998-12-01), Jacobs, Jr. et al.
patent: 5895810 (1999-04-01), Light et al.
patent: 2002/0161197 (2002-10-01), Gawryl et al.
patent: 824375 (1959-11-01), None
patent: 455738 (1975-02-01), None
patent: WO 88/03408 (1988-05-01), None
patent: WO 89/06538 (1989-07-01), None
patent: WO 89/12456 (1989-12-01), None
patent: WO 94/22482 (1994-10-01), None
patent: WO 95/22605 (1995-08-01), None
patent: WO 96/29346 (1996-09-01), None
patent: WO 00/21366 (2000-04-01), None
Cheung et al., “The Preparation of Stroma-Free Hemoglobin by Selective DEAE-Cellulose Absorption,”Analytical Biochemistry, 137:481-484 (1984).
Cole et al., “Focal Cerebral Ischemia in Rats: Effect of Hemodilution with α-α Cross-Linked Hemoglobin on CBF,”J. Cereb. Blood Flow Metab., 12(6):971-976 (1992).
De Venuto et al., “Characteristics of stroma-free hemoglobin prepared by crystallization,”J. Lab Clin. Med., 89(3):509-516 (1977).
DeVenuto et al., “Appraisal of Hemoglobin Solution as a Blood Substitute,”Surgery, Gynecology, &Obstetrics, 149(3):417-436 (1979).
Feola et al., “Development of a Bovine Stroma-Free Hemoglobin Solution as a Blood Substitute,”Surgery, Gynecology&Obstetrics, 157(5):399-408 (1983).
Gibbs, “Artificial Blood Quickens,”Scientific American, [online] [retrieved on Feb. 14, 2001]. Retrieved from Internet: <URL:http://sciam.com/0996issue/0996techbus4.html>.
Hamilton et al., “Preparation of Hemoglobin Solutions for Intravenous Infusion,”J. Exp. Med., 86:455-463 (1947).
Sehgal et al., “Polymerized pyridoxylated hemoglobin: A red cell substitute with normal oxygen capacity,”Surgery, 95(4):433-438 (1984).
Ritter, “Passing a Blood Test,”Chemical&Engineering, 76:37-44 (1998).
Savitsky et al., “A clinical safety trial of stroma-free hemoglobin,”Clin. Pharmacol. Ther., 23(1):73-80 (1978).
Sharma et al., “An Isologous Porcine Promoter Permits High Level Expression in Human Hemoglobin in Transgenic Swine,”Bio/Technology,12:55-59 (1994).
Teicher et al., “Oxygenation of tumors by a hemoglobin solution,”J. Cancer Res. Clin Oncol., 120:85-90 (1993).
Bray et al., “Defibrination of normal human blood in vitro: a method giving a high recovery of untraumatized cells,”British Journal of Haematology, 35(4):551-559 (1977)(From Database Medline, 1997, Abstract No. NLM871408.
Kay et al., “Rapid recovery of non-hemolyzed serum and untraumatized cells by using a new method of blood defibrination in vitro,”J. of Immunological Methods, 92(2):251-260 (1986).
Topping et al., “Effects of insulin on the metabolism of the isolated working rat heart perfused with undiluted rat blood,”Biochimica et Biophysica Acta, 844(2):113-118 (1985).
Alcorta, I., et al., “Influence of the Red Blood Cell Preparation Method on the Efficacy of a Leukocyte Reduction Filter,”Vox Sanguinis, 71:78-83 (1996).
Baróti Tóth, C. et al., “IgA Content of Washed Red Blood Cell Concentrates,”Vox Sanguinis, 74:13-14 (1998).
Spain, David A. et al., “Quality Assessment of Intraoperative Blood Salvage and Autotransfusion,”The American Surgeon, 63:1059-1064 (1997).
Gawryl Maria S.
Houtchens Robert A.
Light William R.
Biopure Corporation
Hamilton Brook Smith & Reynolds P.C.
Srivastava Kailash C
Weber Jon P
LandOfFree
Use of defibrinated blood for manufacture of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of defibrinated blood for manufacture of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of defibrinated blood for manufacture of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113752